Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-06, Stock:LLY, The news for the past five days is as follows:
2018-07-30: NEWS1: What to Expect from Incyte’s Q2 2018 Earnings on July 31.NEWS2: How Celgene’s Otezla and Abraxane Did in Q2 2018.NEWS3: A Look at Celgene’s Financials in Q2 2018.NEWS4: WisdomTree U.S. Dividend ex-Financials Fund -- Insider Buying Index Registering 10.2%.NEWS5: WisdomTree U.S. Dividend ex-Financials Fund -- Insider Buying Index Registering 10.2%.NEWS6: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS7: Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute.
2018-07-31: NEWS1: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS2: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS3: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS4: Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss.NEWS5: Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss.NEWS6: November 16th Options Now Available For Eli Lilly.NEWS7: November 16th Options Now Available For Eli Lilly.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: What Analysts Recommend for Celgene Stock.
2018-08-01: NEWS1: Here's What's Going On at Eli Lilly and GlaxoSmithKline.NEWS2: Here's What's Going On at Eli Lilly and GlaxoSmithKline.NEWS3: Here&apos;s What&apos;s Going On at Eli Lilly and GlaxoSmithKline.NEWS4: Eli Lilly’s Q2 2018 Earnings: Human Pharmaceuticals Business.NEWS5: A Look at Merck’s Financial Position.NEWS6: Why The 'Heat Wave' For U.S. Pharma Could Continue This Month.NEWS7: Eli Lilly’s Q2 2018 Earnings: How Did Its Segments Perform?.NEWS8: Most Analysts Recommended a ‘Buy’ for Merck at End of July.NEWS9: Healthcare Bulls Are Feeling Great After Earnings.NEWS10: Eli Lilly: 9% Revenue Growth in Q2 2018 Exceeded Estimates.NEWS11: Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability.NEWS12: [$$] Trump is losing the war on drug prices.NEWS13: [$$] Trump’s fight with drugmakers will not solve healthcare crisis.
2018-08-02: NEWS1: Drugmaker Lilly's Elanco animal health unit files for IPO.NEWS2: Diabetes Superpower Eli Lilly's Results.NEWS3: Diabetes Superpower Eli Lilly's Results.NEWS4: Drugmaker Lilly's Elanco animal health unit files for IPO.NEWS5: Eli Lilly's Animal-Health Business Files for Initial Public Offering.NEWS6: Elanco Animal Health Files IPO Registration Statement.NEWS7: Diabetes Superpower Eli Lilly&apos;s Results.NEWS8: United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip.NEWS9: United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip.NEWS10: Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?.NEWS11: Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?.NEWS12: Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018.NEWS13: What DexCom Just Said About Its Future.NEWS14: What DexCom Just Said About Its Future.NEWS15: Eli Lilly’s Q2 2018 Earnings: Oncology Products.NEWS16: Pfizer’s Xeljanz Receives Marketing Authorization in EU.NEWS17: How Is Merck’s Diabetes and Women’s Health Business Positioned?.NEWS18: LLY’s Cardiovascular Products: Cialis and Effient Q2 Sales Fall.
2018-08-03: NEWS1: Analysts Raise Target Prices for TEVA after Its Q2 2018 Results.NEWS2: What Pushed Teva’s Earnings Above Analysts’ Estimate.NEWS3: Teva Falls 9.5% as Q2 Sales Miss Analysts’ Estimate.NEWS4: Eli Lilly Breaks Out of a Large Consolidation Pattern, Further Gains Ahead.NEWS5: United Therapeutics: Analyst Recommendations, Product Performance.NEWS6: Eli Lilly’s Q2 2018 Earnings: Key Developments.NEWS7: Eli Lilly’s Q2 2018 Earnings: Elanco.NEWS8: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings.NEWS9: Eli Lilly’s Q2 2018 Earnings: New Products.NEWS10: Jim Cramer: 4 Pet-Related Stocks That Are Top Dog.

Answer: Rise